SDHAF2 Gene

Ver.	Summary	Created by	Modification	Content Size	Created at	Operation
1		Karina Chen	+ 426 word(s)	426	2020-12-15 08:08:24

This entry is adapted from https://medlineplus.gov/genetics/gene/sdhaf2

succinate dehydrogenase complex assembly factor 2

genes

Information

Subjects: Genetics & Heredity

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Karina Chen

View Times: 150

Entry Collection: MedlinePlus

Update Date: 24 Dec 2020

Table of Contents

1. Normal Function

The SDHAF2 gene provides instructions for making a protein that interacts with the succinate dehydrogenase (SDH) enzyme. The SDHAF2 protein helps a molecule called FAD attach to the SDH enzyme. FAD is called a cofactor because it helps the enzyme carry out its function. The FAD cofactor is required for SDH enzyme activity.

The SDH enzyme plays a critical role in mitochondria, which are structures inside cells that convert the energy from food into a form that cells can use. Within mitochondria, the SDH enzyme links two important pathways in energy conversion: the citric acid cycle (or Krebs cycle) and oxidative phosphorylation. As part of the citric acid cycle, the SDH enzyme converts a compound called succinate to another compound called fumarate.

Succinate, the compound on which the SDH enzyme acts, is an oxygen sensor in the cell and can help turn on specific pathways that stimulate cells to grow in a low-oxygen environment (hypoxia). In particular, succinate stabilizes a protein called hypoxia-inducible factor (HIF) by preventing a reaction that would allow HIF to be broken down. HIF controls several important genes involved in cell division and the formation of new blood vessels in a hypoxic environment.

The SDHAF2 gene is a tumor suppressor, which means it prevents cells from growing and dividing in an uncontrolled way.

2. Health Conditions Related to Genetic Changes

2.1. Hereditary paraganglioma-pheochromocytoma

At least one mutation in the SDHAF2 gene has been identified in people with hereditary paraganglioma-pheochromocytoma type 2. People with this condition have paragangliomas, pheochromocytomas, or both. These noncancerous (benign) tumors are associated with the nervous system. The mutation replaces a protein building block (amino acid) in the SDHAF2 protein. Specifically, the amino acid glycine is replaced with the amino acid arginine at position 78 (written as Gly78Arg or G78R). The interaction between the mutated SDHAF2 protein and the SDH complex is impaired, and attachment of the FAD cofactor is decreased. As a result, the SDH enzyme is nonfunctional. Because the mutated SDH enzyme cannot convert succinate to fumarate, succinate accumulates in the cell. Excess succinate abnormally stabilizes HIF, which also builds up in cells. Excess HIF stimulates cells to divide and triggers the production of blood vessels when they are not needed. Rapid and uncontrolled cell division, along with the formation of new blood vessels, can lead to the development of tumors in people with hereditary paraganglioma-pheochromocytoma.

3. Other Names for This Gene

C11orf79
FLJ20487
hSDH5
PGL2
SDH assembly factor 2
SDH5
SDHF2_HUMAN
succinate dehydrogenase assembly factor 2, mitochondrial
succinate dehydrogenase subunit 5, mitochondrial

References

Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E,Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Suárez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Knijff P, Lenders JW,Cremers CW, Devilee P, Dinjens WN, de Krijger RR, Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010Apr;11(4):366-72. doi: 10.1016/S1470-2045(10)70007-3.
Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, DevileeP, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, Rutter J.SDH5, a gene required for flavination of succinate dehydrogenase, is mutated inparaganglioma. Science. 2009 Aug 28;325(5944):1139-42. doi:10.1126/science.1175689.
Müller U. Pathological mechanisms and parent-of-origin effects in hereditaryparaganglioma/pheochromocytoma (PGL/PCC). Neurogenetics. 2011 Aug;12(3):175-81.doi: 10.1007/s10048-011-0280-y.
Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrinetumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med.2009 Jul;266(1):19-42. doi: 10.1111/j.1365-2796.2009.02111.x. Review.
Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T,Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR,Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, TomlinsonIP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha intumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005 Aug 1;14(15):2231-9.
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, PanY, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction tooncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005Jan;7(1):77-85.

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry